Overview
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Eligibility
Inclusion Criteria:
- Patients with CD
- ≥ 18 to ≤ 75 years-old
- Symptomatic CD according to PRO-2 (stool \> 3 or abdominal pain score \> 1)
- Transmural inflammation on baseline MRI (C-score \> 0.5 in at least one segment)
Exclusion Criteria:
- Prior exposure to anti-p19 biological therapy
- Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase \[JAK\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents
- Exclude any previous use of p19 IL23s agents
- Contra-indication to mirikizumab
- Definitive ostomy
- Colectomy with IPAA
- Isolated or uncontrolled perianal lesions
- Severe obstructive symptoms
- Intra-abdominal abscess
- Contra-indication to MRI
- No health insurance
- Pregnant or lactating women
- Patients already included in biomedical research other than an observational study (e.g., registry, cohort)
- Concomitant Clostridioides difficile infection
- HIV infection
- Patient under guardianship, curatorship or safeguard of justice
